Nothing Special   »   [go: up one dir, main page]

PE20151138A1 - Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n - Google Patents

Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n

Info

Publication number
PE20151138A1
PE20151138A1 PE2015000206A PE2015000206A PE20151138A1 PE 20151138 A1 PE20151138 A1 PE 20151138A1 PE 2015000206 A PE2015000206 A PE 2015000206A PE 2015000206 A PE2015000206 A PE 2015000206A PE 20151138 A1 PE20151138 A1 PE 20151138A1
Authority
PE
Peru
Prior art keywords
alkyl
calcium channel
channel blockers
type calcium
pyrazoles substituted
Prior art date
Application number
PE2015000206A
Other languages
English (en)
Inventor
Mark Wall
Nalin Subasinghe
Zhihua Sui
Christopher Flores
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49034268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151138(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20151138A1 publication Critical patent/PE20151138A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion se refiere a compuestos, composiciones y metodos para el tratamiento de varias enfermedades, sindromes, afecciones y trastornos, que incluyen el dolor. Tales compuestos se representan por la Formula (I) donde: R1 es alquilo de C1-4, alcoxi de C1-4, di(alquilo de C1-4) amino, cloro, entre otros, el anillo A es fenilo o un heteroarilo seleccionado del grupo que consiste en piridinilo, tienilo, benzofuranilo, quinolinilo, e indolilo; R2 es alquilo de C1-4, alcoxi de C1-4, alquiltio de C1-4, entre otros, G es G1, G2, G3, o G4; Q es O, S, SO2, entre otros, W es O, S,CH(OH), entre otros, R3 y R4 son 2,2,2-trifluoroetilo, di(alquilo de C1-4) aminocarbonilo, N-metoxi-N-metilaminocarbonilo, entre otros, R5 es trifluorometilcarbonilamino, amino, o alcoxicarbonilamino de C1-4
PE2015000206A 2012-08-16 2013-08-16 Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n PE20151138A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261683774P 2012-08-16 2012-08-16

Publications (1)

Publication Number Publication Date
PE20151138A1 true PE20151138A1 (es) 2015-08-07

Family

ID=49034268

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000206A PE20151138A1 (es) 2012-08-16 2013-08-16 Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n

Country Status (18)

Country Link
US (1) US9434693B2 (es)
EP (1) EP2885278B1 (es)
JP (1) JP6262732B2 (es)
KR (1) KR20150042269A (es)
CN (1) CN104884438B (es)
AU (1) AU2013302468B2 (es)
BR (1) BR112015003393A2 (es)
CA (1) CA2882038A1 (es)
CL (1) CL2015000360A1 (es)
CR (1) CR20150067A (es)
EA (1) EA201590381A1 (es)
IL (1) IL237190A0 (es)
IN (1) IN2015DN01238A (es)
MX (1) MX2015002036A (es)
PE (1) PE20151138A1 (es)
PH (1) PH12015500316A1 (es)
SG (1) SG11201501130PA (es)
WO (1) WO2014028800A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974775B2 (en) 2013-08-16 2018-05-22 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2888285B1 (en) 2012-08-21 2024-04-17 Janssen Pharmaceutica NV Antibodies to aripiprazole haptens and use thereof
EP2888593B1 (en) 2012-08-21 2018-09-19 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
JP6242893B2 (ja) 2012-08-21 2017-12-06 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンに対する抗体及びその使用
PT2888286T (pt) 2012-08-21 2018-05-09 Janssen Pharmaceutica Nv Anticorpos para haptenos de quetiapina e sua utilização
ES2807902T3 (es) 2012-08-21 2021-02-24 Janssen Pharmaceutica Nv Anticuerpos para olanzapina y uso de los mismos
ES2652641T3 (es) 2012-08-21 2018-02-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
TW201726128A (zh) * 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
TW201718557A (zh) * 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
US10444250B2 (en) 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
CN108368180B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 喹硫平的抗体及其用途
US20200002283A1 (en) * 2016-06-29 2020-01-02 Esteve Pharmaceuticals, S.A. Pyrazole derivatives having activity against pain

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
IT1287174B1 (it) 1996-11-15 1998-08-04 Angelini Ricerche Spa Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
WO2004060367A1 (en) * 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2005033073A2 (en) 2003-10-01 2005-04-14 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
FR2864958B1 (fr) 2004-01-12 2006-02-24 Sanofi Synthelabo Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
WO2009000085A1 (en) * 2007-06-27 2008-12-31 Painceptor Pharma Corporation Quinoline and quinazoline derivatives useful as modulators of gated ion channels
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
EP2676956A1 (en) 2008-08-01 2013-12-25 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
KR101052065B1 (ko) * 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
BR112015003328A2 (pt) 2012-08-16 2017-07-04 Janssen Pharmaceutica Nv ciclopentilpirazóis como bloqueadores de canal de cálcio de tipo-n
ES2600743T3 (es) 2012-08-16 2017-02-10 Janssen Pharmaceutica, N.V. Pirazoles sustituidos como bloqueantes del canal de calcio tipo N
PE20151139A1 (es) 2012-08-16 2015-08-07 Janssen Pharmaceutica Nv Pirrolopirazoles como bloqueadores del canal de calcio tipo n

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974775B2 (en) 2013-08-16 2018-05-22 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Also Published As

Publication number Publication date
KR20150042269A (ko) 2015-04-20
PH12015500316A1 (en) 2015-03-30
EP2885278A1 (en) 2015-06-24
AU2013302468B2 (en) 2017-08-24
JP6262732B2 (ja) 2018-01-17
BR112015003393A2 (pt) 2017-07-04
EP2885278B1 (en) 2016-08-03
WO2014028800A1 (en) 2014-02-20
AU2013302468A1 (en) 2015-02-26
CA2882038A1 (en) 2014-02-20
CN104884438A (zh) 2015-09-02
IL237190A0 (en) 2015-04-30
CN104884438B (zh) 2017-07-28
US20140162997A1 (en) 2014-06-12
CR20150067A (es) 2015-04-30
US9434693B2 (en) 2016-09-06
CL2015000360A1 (es) 2015-04-24
SG11201501130PA (en) 2015-04-29
EA201590381A1 (ru) 2015-07-30
JP2015524850A (ja) 2015-08-27
MX2015002036A (es) 2016-01-22
IN2015DN01238A (es) 2015-06-26

Similar Documents

Publication Publication Date Title
PE20151138A1 (es) Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n
NI201000013A (es) Sulfonamidas como moduladores del trpm8
PE20151139A1 (es) Pirrolopirazoles como bloqueadores del canal de calcio tipo n
CR9048A (es) Analogos de anilino-pirimidina
HN2011000341A (es) Compuestos derivados de sulfonamidas, composiciones farmaceuticos y proceso de preparacion de los mismos
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
PE20191204A1 (es) Modificador del sabor dulce
EA201500557A1 (ru) Антигельминтные соединения, композиции и способы их применения
EA201590868A1 (ru) Противовирусные соединения
PE20180030A1 (es) Compuestos biciclicos de sulfonamida cetona
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
PH12015502192A1 (en) Novel compounds
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
EA201790963A1 (ru) Противовирусные соединения
EA200870497A1 (ru) Бензимидазольные модуляторы vr1
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
PE20151140A1 (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
MX2012012902A (es) Analogos heteroarilo biciclicos como moduladores de receptor acoplado a la proteina g gpr119.
PE20191478A1 (es) Compuestos moduladores del receptor de hidorcarburos de arilo (ahr)
PE20151429A1 (es) Dihidropirimidinonas biciclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofilica
PE20191479A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
AR087515A1 (es) Compuestos de n-tio-antranilamida y sus usos como plaguicidas
DK2190426T3 (da) Griseofulvin-analoger til behandling af cancer ved hæmning af centrosomal clusterdannelse
PE20151748A1 (es) Inhibidores de bace1
PE20150774A1 (es) Aminoquinolinas como inhibidores de cinasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed